Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2005

01-05-2005 | Case Report

Response to Imatinib Mesylate in a Patient with Idiopathic Hypereosinophilic Syndrome Associated with Cyclic Eosinophil Oscillations

Authors: Shinsaku Imashuku, Naoki Kakazu, Ikuyo Ueda, Akira Morimoto, Hironori Harada, Tomoko Teramura, Shinichi Tamura, Yoko Fukushima-Nakase, Hiroshi Kuroda

Published in: International Journal of Hematology | Issue 4/2005

Login to get access
Metadata
Title
Response to Imatinib Mesylate in a Patient with Idiopathic Hypereosinophilic Syndrome Associated with Cyclic Eosinophil Oscillations
Authors
Shinsaku Imashuku
Naoki Kakazu
Ikuyo Ueda
Akira Morimoto
Hironori Harada
Tomoko Teramura
Shinichi Tamura
Yoko Fukushima-Nakase
Hiroshi Kuroda
Publication date
01-05-2005
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2005
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.04185

Other articles of this Issue 4/2005

International Journal of Hematology 4/2005 Go to the issue

Case Report

Aplastic Anemia in a Professional Musician Exposed to Instrument Polish

OriginalPaper

Roles of a trithorax Group Gene, MLL, in Hematopoiesis

Case Report

Fatal Fulminant Hepatitis B after Withdrawal of Prophylactic Lamivudine in Hematopoietic Stem Cell Transplantation Patients

Case Report

Extramedullary Blast Crisis Derived from 2 Different Clones in the Central Nervous System and Neck during Complete Cytogenetic Remission of Chronic Myelogenous Leukemia Treated with Imatinib Mesylate

OriginalPaper

Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma: Results from the Japan Myeloma Study Group

Letter to the Editor

Infliximab-Associated Lymphoproliferative Disorders
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits